FDA approves apalutamide for treatment of mCSPC here in US

Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …

Enzalutamide extends OS compared to an standard antiandrogen in ENZAMET trial, but …

The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Full results of apalutamide in treatment of mHSPC

At the end of January, we had reported that the results of the TITAN trial — the Phase III trial of standard ADT + apalutamide (Erlead) or standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer (mHSPC) — were positive, and that they were going to be reported at a meeting later in the year. … READ MORE …

ENZAMET trial results to be presented at ASCO

The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …

Results from the ARCHES trial presented yesterday in San Francisco

On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …

Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Contemporary questions about the initial treatment of advanced forms of prostate cancer

So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …